Related Experiment Video
Updated: Aug 4, 2026

Isolation of Labile Multi-protein Complexes by in vivo Controlled Cellular Cross-Linking and Immuno-magnetic Affinity Chromatography
Published on: March 9, 2010
Complex between Peptostreptococcus magnus protein L and a human antibody reveals structural convergence in the
M Graille1, E A Stura, N G Housden
1Département d'Ingénierie et d'Etudes des Protéines, Commissariat à l'Energie Atomique, Centre d'Etudes Saclay, F-91191, Gif-sur-Yvette, France.
Background:
Peptostreptococcus magnus protein L (PpL) is a multidomain, bacterial surface protein whose presence correlates with virulence. It consists of up to five homologous immunoglobulin binding domains that interact with the variable (VL) regions of kappa light chains found on two thirds of mammalian antibodies.
Results:
We refined the crystal structure of the complex between a human antibody Fab fragment (2A2) and a single PpL domain (61 residues) to 2.7 A. The asymmetric unit contains two Fab molecules sandwiching a single PpL domain, which contacts similar VL framework regions of two light chains via independent interfaces. The residues contacted on VL are remote from the hypervariable loops. One PpL-Vkappa interface agrees with previous biochemical data, while the second is novel. Site-directed mutagenesis and analytical-centrifugation studies suggest that the two PpL binding sites have markedly different affinities for VL. The PpL residues in both interactions are well conserved among different Peptostreptococcus magnus strains. The Fab contact positions identified in the complex explain the high specificity of PpL for antibodies with kappa rather than lambda chains.
Conclusions:
The PpL-Fab complex shows the first interaction of a bacterial virulence factor with a Fab light chain outside the conventional combining site. Structural comparison with two other bacterial proteins interacting with the Fab heavy chain shows that PpL, structurally homologous to streptococcal SpG domains, shares with the latter a similar binding mode. These two bacterial surface proteins interact with their respective immunoglobulin regions through a similar beta zipper interaction.
Insights
Peptostreptococcus magnus protein L (PpL) binds to human antibody light chains outside the typical antigen-binding site. This bacterial virulence factor interacts with kappa light chains via two distinct interfaces, explaining its specificity.
Area of Science:
- Structural biology
- Immunology
- Microbial pathogenesis
Background:
- Peptostreptococcus magnus protein L (PpL) is a bacterial surface protein associated with virulence.
- PpL possesses immunoglobulin-binding domains that interact with the variable light (VL) regions of kappa light chains in mammalian antibodies.
Purpose of the Study:
- To elucidate the structural basis of the interaction between a single PpL domain and a human antibody Fab fragment.
- To understand the molecular mechanisms underlying PpL's specificity for kappa light chains.
Main Methods:
- Refined crystal structure analysis of the PpL-Fab complex at 2.7 Å resolution.
- Site-directed mutagenesis and analytical ultracentrifugation to assess binding affinities.
Main Results:
- The crystal structure revealed two independent binding interfaces between a single PpL domain and two antibody Fab molecules, targeting VL framework regions.
- One interface confirmed previous biochemical data, while the second was novel.
- PpL binding sites exhibited differential affinities for VL, and PpL residues involved are conserved across bacterial strains.
- The identified contact points explain PpL's specificity for kappa over lambda light chains.
Conclusions:
- This study presents the first structure of a bacterial virulence factor binding to an antibody light chain outside the conventional antigen-binding site.
- PpL shares a similar binding mode and beta-zipper interaction with streptococcal protein G (SpG) domains, another bacterial protein that binds immunoglobulin.
- The findings offer insights into bacterial immune evasion strategies and potential therapeutic targets.
More Related Videos
14:58Identification of Protein Complexes in Escherichia coli using Sequential Peptide Affinity Purification in Combination with Tandem Mass Spectrometry
Published on: November 12, 2012
18:27One-step Purification of Twin-Strep-tagged Proteins and Their Complexes on Strep-Tactin Resin Cross-linked With Bis(sulfosuccinimidyl) Suberate (BS3)
Published on: April 20, 2014
Related Concept Videos
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Protein-protein Interfaces
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
Antibody Structure and Classes
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...